Adverse drug events in children: the US Food and Drug Administration perspective
- 1 October 2001
- journal article
- Published by Elsevier in Current Therapeutic Research
- Vol. 62 (10) , 711-723
- https://doi.org/10.1016/s0011-393x(01)80078-3
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models.Environmental Health Perspectives, 2000
- Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting SystemThe American Statistician, 1999
- [Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System]: ReplyThe American Statistician, 1999
- [Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System]: DiscussionThe American Statistician, 1999
- [Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System]: DiscussionThe American Statistician, 1999
- [Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System]: DiscussionThe American Statistician, 1999
- Reye's Syndrome in the United States from 1981 through 1997New England Journal of Medicine, 1999
- The developmental toxicity of three antimicrobial agents observed only in nonroutine animal studiesReproductive Toxicology, 1997
- Phenobarbital for Febrile Seizures — Effects on Intelligence and on Seizure RecurrenceNew England Journal of Medicine, 1990
- Two-compartment gentamicin pharmacokinetics in premature neonates: A comparison to adults with decreased glomerular filtration ratesThe Journal of Pediatrics, 1980